Aquestive Therapeutics, Inc.

Aquestive is a pharmaceutical company focused on developing medicines using innovative science and delivery technologies. The company aims to provide alternatives to invasive standard-of-care therapies by delivering complex molecules through non-invasive administrations. Aquestive is advancing Anaphylm™, a late-stage non-device based epinephrine prodrug product candidate for severe allergic reactions, including anaphylaxis, and its AdrenaVerse™ epinephrine prodrug pipeline platform. Aquestive has four licensed commercialized products, which are marketed globally by its licensees. The company is the exclusive manufacturer of these licensed products. Aquestive also collaborates with other pharmaceutical companies, utilizing proprietary technologies such as PharmFilm®, and possesses drug development and commercialization capabilities. The company's production facilities are located in Portage, Indiana, while its corporate headquarters and primary research laboratory facilities are in Warren, New Jersey. Aquestive manufactures licensed products at its facilities and anticipates its current manufacturing capacity is sufficient for commercial quantities of its licensed products and proprietary product candidates in development. Its facilities have been inspected by the FDA, TGA, and DEA, and are subject to inspection by other health agencies, including ANVISA and EMA. Aquestive is a worldwide leader in oral film drug delivery and manufacturing, having historically supplied the substantial majority of the world's oral films for prescription pharmaceutical use and shipped over two billion doses globally. Its PharmFilm® technology uses proprietary polymer compositions as film formers for active pharmaceutical ingredients (APIs) and excipients.